research use only

Teniposide Topoisomerase inhibitor

Cat.No.S1787

Teniposide (NSC 122819, VM-26) is a chemotherapeutic medication mainly used in the treatment of childhood acute lymphocytic leukemia (ALL).
Jump to

Quality Control

Batch: Purity: 99.57%
99.57

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (152.28 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 656.65 Formula

C32H32O13S

Storage (From the date of receipt)
CAS No. 29767-20-2 Download SDF Storage of Stock Solutions

Synonyms NSC 122819, VM-26 SMILES COC1=CC(=CC(=C1O)OC)C2C3C(COC3=O)C(C4=CC5=C(C=C24)OCO5)OC6C(C(C7C(O6)COC(O7)C8=CC=CS8)O)O

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC50/Ki
Topoisomerase II
References

Applications

Methods Biomarkers Images PMID
Western blot CETP p21 / pRb / E2F1 MYB
S1787-WB1
25914138
Immunofluorescence α-CETP α-LXRα / α-LXRβ
S1787-IF1
25914138

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2025-07-20)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT07074470 RECRUITING
Primary Central Nervous System Lymphoma (PCNSL)
The First Affiliated Hospital of Soochow University
2025-01-02
NCT07185373 RECRUITING
Primary Central Nervous System Lymphoma
Huashan Hospital
2025-10-01 PHASE2; PHASE3
NCT07583511 RECRUITING
Small-cell Lung Cancer
Sun Yat-sen University
2024-02-01 PHASE2
NCT07188441 RECRUITING
GCT; Germ Cell Tumor; Central Malignant Germ Cell Tumor
Chengcheng Guo
2024-08-13 PHASE2
NCT06758700 RECRUITING
Extensive-stage Small Cell Lung Cancer (ES-SCLC); Thoracic Neoplasms; Lung Neoplasms; Lung Diseases
Shanghai Pulmonary Hospital, Shanghai, China
2025-02-07 PHASE2
NCT06048107 UNKNOWN
HLH
Beijing Friendship Hospital
2023-10-22

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map